Dean Investment Associates Lifted By $508,860 Its Price T Rowe Group (TROW) Holding; 10 Analysts Covering uniQure N.V. (QURE)

January 18, 2018 - By wolcottdaily

Dean Investment Associates Llc increased Price T Rowe Group Inc (TROW) stake by 19.17% reported in 2017Q3 SEC filing. Dean Investment Associates Llc acquired 5,654 shares as Price T Rowe Group Inc (TROW)’s stock declined 0.66%. The Dean Investment Associates Llc holds 35,154 shares with $3.19M value, up from 29,500 last quarter. Price T Rowe Group Inc now has $28.06B valuation. The stock decreased 0.51% or $0.59 during the last trading session, reaching $115.79. About 1.43M shares traded or 1.08% up from the average. T. Rowe Price Group, Inc. (NASDAQ:TROW) has declined 4.22% since January 18, 2017 and is downtrending. It has underperformed by 20.92% the S&P500.

Among 13 analysts covering uniQure N.V. (NASDAQ:QURE), 10 have Buy rating, 0 Sell and 3 Hold. Therefore 77% are positive. uniQure N.V. had 28 analyst reports since August 7, 2015 according to SRatingsIntel. The firm has “Buy” rating by Janney Capital given on Wednesday, January 3. The rating was downgraded by Piper Jaffray on Wednesday, November 16 to “Neutral”. As per Tuesday, September 1, the company rating was downgraded by Zacks. The company was maintained on Monday, September 21 by Oppenheimer. The firm earned “Buy” rating on Monday, September 21 by Roth Capital. The firm has “Buy” rating by Evercore given on Tuesday, November 7. The stock of uniQure N.V. (NASDAQ:QURE) has “Hold” rating given on Tuesday, November 22 by Jefferies. On Wednesday, July 12 the stock rating was maintained by Cowen & Co with “Buy”. The stock of uniQure N.V. (NASDAQ:QURE) has “Buy” rating given on Monday, August 21 by Oppenheimer. The firm earned “Buy” rating on Tuesday, December 1 by WallachBeth Capital. See uniQure N.V. (NASDAQ:QURE) latest ratings:

03/01/2018 Broker: Janney Capital Rating: Buy New Target: $25.0 Initiate
01/12/2017 Broker: H.C. Wainwright Rating: Buy New Target: $28 Initiates Coverage On
07/11/2017 Broker: Evercore Rating: Buy New Target: $22.0 Initiate
21/08/2017 Broker: Oppenheimer Rating: Buy New Target: $17.0 Maintain

uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company has market cap of $552.99 million. The companyÂ’s principle programs include AMT-060, a gene therapy that has completed Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical product candidate for the treatment of congestive heart failure; and AMT-130 for the treatment of huntington's disease. It currently has negative earnings. It also provides Glybera, a gene therapy product that has approved for the treatment of patients with lipoprotein lipase deficiency.

The stock decreased 0.99% or $0.18 during the last trading session, reaching $18. About 320,906 shares traded. uniQure N.V. (NASDAQ:QURE) has declined 52.65% since January 18, 2017 and is downtrending. It has underperformed by 69.35% the S&P500.

Dean Investment Associates Llc decreased Cato Corp (NYSE:CATO) stake by 65,742 shares to 170,190 valued at $2.25 million in 2017Q3. It also reduced Lexington Realty Trust (NYSE:LXP) stake by 65,760 shares and now owns 613,370 shares. Invesco Ltd (NYSE:IVZ) was reduced too.

Since August 31, 2017, it had 0 insider purchases, and 8 selling transactions for $16.11 million activity. Alderson Christopher D had sold 91,605 shares worth $9.46 million on Monday, December 18. 30,000 shares were sold by Wiese Edward A, worth $3.06 million on Wednesday, December 13. Shares for $839,833 were sold by MORELAND KENNETH V. The insider WHITTEMORE ANNE M sold $377,321. $84,292 worth of T. Rowe Price Group, Inc. (NASDAQ:TROW) was sold by Hiebler Jessica M. On Thursday, December 14 HRABOWSKI FREEMAN A III sold $406,356 worth of T. Rowe Price Group, Inc. (NASDAQ:TROW) or 4,000 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: